India’s drug regulator (DCGI) has raised an alarm after several batches of Novo Nordisk medicines, including insulin formulations (Ryzodeg, Fiasp) and the popular weight-loss injection Wegovy (semaglutide), were stolen during transport from the company’s Bhiwandi hub to multiple cities.2025-08-31T18:30:00Z
Why it’s risky:
These drugs need strict cold-chain storage (2–8°C). If they are mishandled, their safety and effectiveness can be compromised, posing serious risks to patients.
Regulator’s advisory:
Doctors must prescribe cautiously and advise patients to report side effects.
Patients should buy only from authorized pharmacies with proper invoices.
State regulators are told to monitor the market strictly and take action under the Drugs & Cosmetics Act, 1940.
Company response (Novo Nordisk)
Confirmed the theft of a minor quantity during transit.
Assured full cooperation with authorities.
Re-emphasized cold-chain integrity and patient safety.
Urged patients to use only genuine, authorized sources. Why it matters:
We are already in high demand worldwide, and compromised or counterfeit versions entering the market could harm patients relying on insulin and obesity treatments.
I READ THIS IN NEWS TODAY & WANTED TO SHARE HERE ?
This is a serious concern. Cold-chain breaches in insulin or semaglutide can make them unsafe. Along with strict regulatory checks, all HCPs must guide patients on buying only from trusted sources and watching for quality issues.
The fact that these vital drugs could be compromised due to a lack of cold chain storage is incredibly dangerous. It highlights the critical need for a secure supply chain to ensure patient safety.
This is serious concern. I hope they find the culprits and stolen batch and destroy that batch of they got corrupted because of cold-chain integrity problem.
The cause of concern runs much deeper for me here considering that first insulin is a very important vital and lifesaving drug in many scenarios and second semaglutide aka ozempic which recently came in news as the weight loss drug is being stolen and then if given in the wrong hands (plus without cold chain) i can only fathom what all things can go wrong.
The rising cases of insulin and obesity drug theft in India raise serious concerns about patient safety and misuse in the black market. A regulatory safety alert is a timely reminder that life-saving and high-demand medications need stronger supply chain security, better monitoring, and stricter enforcement to prevent diversion. Protecting these essential drugs is not just about regulation—it is about safeguarding patients who truly depend on them.
It is very serious .This can be hazardous to patient. I think pharma company should make something like “INSULIN VIAL MONITOR” based on vaccine vial monitor technology compulsory for these drugs too. It will help in cold chain monitoring , potency , efficacy and ensure patient safety
It’s a serious concern especially with medicines like insulin and semaglutide where storage conditions directly affect safety. Patients really need to be extra cautious until things are cleared.
Alarming alert from regulators, The DCGI has notified healthcare professionals and patients about the theft of insulin (Ryzodeg, Fiasp) and Wegovy (semaglutide) batches during transit drugs that require cold-chain storage (2–8 °C). If compromised, these injectables can lose effectiveness or turn unsafe. The regulator urges strict sourcing only from authorized pharmacies with valid invoices and close prescription monitoring.
This is a valid concern. Insulin and semaglutide are the medicines that deal with our hormones when it comes to method of action. Even small mishandling can have serious consequences. Incidents like this show the importance of strict supply chain and regulations monitoring.